Clearside Biomedical (CLSD) Reports In-Line Q4 EPS

Clearside Biomedical (NASDAQ: CLSD) reported Q4 EPS of ($0.10), in-line with the analyst estimate of ($0.10). Revenue for the quarter came in at $306 thousand versus the consensus estimate of $130.14 thousand.

For earnings history and earnings-related data on Clearside Biomedical (CLSD) click here.

You May Also Be Interested In

• EyePoint Pharmaceuticals (EYPT) call put ratio 1.4 calls to 1 put as share price up 8.9%
• Jefferies on Pony AI Inc (PONY): 'overseas expansion is increasingly shifting toward JDM'
• Sypris Solutions (SYPR) Reports Q2 Loss of $0.14